Heidelberg Engineering, based in Franklin, MA, won FDA clearance for its OCT (optical coherence tomography) Angiography Module for the company’s SPECTRALIS eye imaging systems. The offering, used to visualize retinal vasculature in 3D, is available not only on new SPECTRALIS installations, but on existing upgradeable systems as well. OCT Angiography is used along with structural OCT and dye-based angiography to diagnose a variety of eye conditions.
“The addition of OCT angiography to Heidelberg’s SPECTRALIS multimodal platform allows for the evaluation of retinal and choroidal vascular abnormalities in a noninvasive manner,” said Nadia K. Waheed, MD, MPH, Director of the Boston Image Reading Center and Associate Professor of Ophthalmology, Tufts University School of Medicine, in a statement. “I believe OCTA will soon become invaluable in our daily clinical routine for screening and diagnosing chorioretinal disorders.”
SPECTRALIS systems use live eye tracking and dynamic angiography techniques to image the eye
Image: Superficial Vascular Complex, Deep Vascular Complex, and Avascular Complex of the same patient imaged with the SPECTRALIS OCT Angiography Module
Product page: SPECTRALIS OCT Angiography Module…